

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Philippe MSIKA et al. Applicant:

Title: USE OF A COSMETIC OR

PHARMACEUTICAL COMPOSITION

COMPRISING A LUPEOL-RICH EXTRACT AS

AN ACTIVE INGREDIENT FOR

STIMULATING THE SYNTHESIS OF HEAT

SHOCK PROTEINS

Appl. No.: 10/564,785

Filing Date: 1/17/2006

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR §1.56**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the date of entry of the national stage as set forth in 37 CFR §1.491.

RELEVANCE OF EACH DOCUMENT

The literature references provided as Abstracts only are discussed in US 2004/0121030, also cited herein.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date March 13, 2006

FOLEY & LARDNER LLP Customer Number: 22428 Telephone: (202) 672-5569

Facsimile:

(202) 672-5399

By_

Stephen B. Maebius Attorney for Applicant Registration No. 35,264

Styl Bhal

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paper ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control or the control of the

Substitute for form 1449B/PTO Complete if Known **Application Number** 10/564,785 INFORMATION DISCLOSURE STATEMENT BY APPLICANT **Filing Date** 1/17/2006 **First Named Inventor** Philippe MSIKA Date Submitted: March 13, 2006 Group Art Unit Unassigned (use as many sheets as necessary) **Examiner Name** Unassigned Sheet 065691-0430 of Attorney Docket Number

	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant
Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
A1	2004/0121030	A1	PICCIRILLI et al.	06/24/2004	

	No.1	No. ¹ Number	No.1 Number Code ² (if known)	No. 1 Number Code ² (if known) Cited Document	No. 1 Number Code ² (if known) Cited Document MM-DD-YYYY

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Fore Office ³	eign Patent D Number ⁴	ocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
_								

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶			
	A2	DE MEDRANO VILLAR et al., "Triterpenoid compounds from Araujia sericifera B. Effects on the isolated guinea pig ileum," Methods Find. Exp. Clin. Pharmacol., 1997, Vol. 19, No. 8, pp. 515-520 (Abstract).				
	А3	DE MIRANDA et al., "Anti-inflammatory and analgesic activities of the latex containing triterpenes from Himatanthus sucuuba," Planta Med, April 2000, Vol. 66, No. 3, pp. 284-286 (Abstract).				
	A4	KAHLOS et al., "Preliminary tests of antiviral activity of two Inonotus obliquus strains," Fitoterapia, 1996, Vol. 67, No. 4, pp. 344-347 (Abstract).				
	A5	NAGARAJ et al., "Effect of lupeol, a pentacyclic triterpene, on the lipid peroxidation and antioxidant status in rat kidney after chronic cadmium exposure," J. Appl. Toxicol., September 2000, Vol. 20, No. 4, pp. 413-417 (Abstract).				
	A6	SINGH et al., "Anti-inflammatory activity of lupeol," Fitoterapia, 1997, Vol. 68, No. 1, pp. 9-16 (Abstract).				
	A7	ZACHARIAH et al., "Anti-inflammatory and anti-mitotic activities of lupeol isolated from the leaves of lxora coccinea Linn.," Ind. J. Pharm. Sci. 1994, Vol. 56, No. 4, pp. 129-132 (Abstract).				

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MAR 1 3 2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.